A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
STRO-002-GM2
Phase 1 other active
Quick answer
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) for Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers) is a Phase 1 program (other) at SUTRO BIOPHARMA, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SUTRO BIOPHARMA, INC.
- Indication
- Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)
- Phase
- Phase 1
- Modality
- other
- Status
- active